Tocilizumab study offers new hope for children with arthritis A new study has confirmed significant improvements after treatment with tocilizumab amongst children with systemic juvenile idiopathic arthritis (sJIA), who do not tolerate or have an inadequate response to conventional therapies. view more (2006-06-23)
First multinational study of Tocilizumab reports in Nearly half (43.9%) of rheumatoid arthritis (RA) patients receiving tocilizumab 8mg/kg, in addition to ongoing methotrexate therapy experienced a 50% (ACR50) improvement in symptoms at 24 weeks and more than one fifth achieved a 70% symptom improvement. view more (2007-06-18)
